Literature DB >> 9350056

Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with culture confluency, cell cycle phase and serum response.

P J Nelson1, I H Gelman.   

Abstract

We recently identified a novel myristylated protein kinase C (PKC) substrate, named SSeCKS (pronounced essex), whose transcription is suppressed > 15 fold in src- or ras-transformed rodent fibroblasts, but not in raf-transformed cells [1, 2]. SSeCKS associates with and controls the elaboration of a cortical cytoskeletal matrix in response to phorbol esters [2], and overexpression of SSeCKS causes growth arrest of untransformed NIH3T3 cells [3]. Our preliminary data suggested that SSeCKS functions as a negative mitogenic regulator by controlling cytoskeletal architecture and that serine phosphorylation of SSeCKS by kinases such as PKC alters its interaction with cytoskeletal matrices and its ability to control mitogenesis. Here, we determine the effects of culture confluency, growth arrest and serum response on the steady-state abundance of SSeCKS RNA and protein and on the relative level of phosphoserine-free SSeCKS. SSeCKS transcription is initially induced by serum factors and by contact-inhibited growth rather than by cell-cycle arrest induced by serum starvation, hydroxyurea or nocodazole, and following serum-induced G1/S progression, SSeCKS transcription is suppressed. SSeCKS protein is hyperphosphorylated on serine residues during G1/S progression but not during the G2/M phase. Finally, we show that the induction of SSeCKS protein expression by contact inhibition is independent of SSeCKS' serum responsiveness. These data suggest that SSeCKS expression and function can be controlled at either the transcriptional or post-translational level in response to serum factors and culture confluency. The data strengthen the notion that SSeCKS plays an important, yet transient, role in cell cycle progression from G0 to G1 that differs from its role in controlling contact-inhibited growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350056     DOI: 10.1023/a:1006836003758

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

1.  Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin.

Authors:  B Hendey; C B Klee; F R Maxfield
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

2.  Protein expression of the alpha, gamma, delta and epsilon subspecies of protein kinase C changes as C6 glioma cells become contact inhibited and quiescent in the presence of serum.

Authors:  K Moreton; R Turner; N Blake; A Paton; N Groome; M Rumsby
Journal:  FEBS Lett       Date:  1995-09-18       Impact factor: 4.124

3.  Stimulation of receptor protein-tyrosine phosphatase alpha activity and phosphorylation by phorbol ester.

Authors:  J den Hertog; J Sap; C E Pals; J Schlessinger; W Kruijer
Journal:  Cell Growth Differ       Date:  1995-03

Review 4.  Intracellular targeting of protein kinase C isoenzymes: functional implications.

Authors:  S C Kiley; S Jaken; R Whelan; P J Parker
Journal:  Biochem Soc Trans       Date:  1995-08       Impact factor: 5.407

Review 5.  Oncogene-mediated effects on cellular gene expression.

Authors:  A Aoyama; R Klemenz
Journal:  Crit Rev Oncog       Date:  1993

6.  PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.

Authors:  M R Soma; R Baetta; S Bergamaschi; M R De Renzis; C Davegna; F Battaini; R Fumagalli; S Govoni
Journal:  Biochem Biophys Res Commun       Date:  1994-04-29       Impact factor: 3.575

Review 7.  The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies.

Authors:  M Symons
Journal:  Curr Opin Biotechnol       Date:  1995-12       Impact factor: 9.740

8.  Differential effects of the protein kinase C inhibitors H7 and calphostin C on the cell cycle of neuroblastoma cells.

Authors:  M D Miñana; V Felipo; S Grisolía
Journal:  Brain Res       Date:  1992-11-20       Impact factor: 3.252

9.  G1/S control of anchorage-independent growth in the fibroblast cell cycle.

Authors:  T M Guadagno; R K Assoian
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

10.  Phosphorylation of the growth arrest-specific protein Gas2 is coupled to actin rearrangements during Go-->G1 transition in NIH 3T3 cells.

Authors:  C Brancolini; C Schneider
Journal:  J Cell Biol       Date:  1994-03       Impact factor: 10.539

View more
  11 in total

1.  SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.

Authors:  X Lin; P Nelson; I H Gelman
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

Review 2.  Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.

Authors:  Irwin H Gelman
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

3.  SSeCKS is a suppressor in Schwann cell differentiation and myelination.

Authors:  Yuhong Ji; Tao Tao; Chun Cheng; Huiguang Yang; Youhua Wang; Junling Yang; Haiou Liu; Xinxing He; Huiming Wang; Aiguo Shen
Journal:  Neurochem Res       Date:  2009-09-16       Impact factor: 3.996

4.  Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12.

Authors:  Li-Wu Guo; Lingqiu Gao; Julian Rothschild; Bing Su; Irwin H Gelman
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

5.  Involvement of SRC-suppressed C kinase substrate in neuronal death caused by the lipopolysaccharide-induced reactive astrogliosis.

Authors:  Ping Wang; Linlin Sun; Aiguo Shen; Junling Yang; Xiaohong Li; Haiou Liu; Tao Tao; Chun Cheng; Xiang Lu
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

6.  Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.

Authors:  Thomas Wilhelm; Daniel B Lipka; Tania Witte; Justyna A Wierzbinska; Silvia Fluhr; Monika Helf; Oliver Mücke; Rainer Claus; Carolin Konermann; Peter Nöllke; Charlotte M Niemeyer; Christian Flotho; Christoph Plass
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

7.  Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis.

Authors:  Irwin H Gelman
Journal:  Genes Cancer       Date:  2010-11

8.  SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway.

Authors:  Bing Su; Yahao Bu; David Engelberg; Irwin H Gelman
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

9.  Increased SSeCKS expression in rat hepatic stellate cells upon activation in vitro and in vivo.

Authors:  Tiangeng You; Yuanzhi Fan; Qi Li; Yong Gao; Yongkang Yang; Zhongxin Zhao; Congjun Wang
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

10.  Lipopolysaccharide induces expression of SSeCKS in rat lung microvascular endothelial cell.

Authors:  Chun Cheng; Haiou Liu; Haiyan Ge; Ji Qian; Jing Qin; Linlin Sun; Menling Chen; Meijuan Yan; Aiguo Shen
Journal:  Mol Cell Biochem       Date:  2007-06-06       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.